Biogen (BIIB) Could Be Worth $375-475/Share in a Takeover - RBC Capital's Yee
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Biogen (BIIB) Sale Dependent on Value of Aducanumab - BMO Capital
August 3, 2016 7:52 AM EDTBMO Capital analyst M. Ian Somaiya weighed in on Biogen (NASDAQ: BIIB) amid reports Tuesday that the company is in talks with Merck and Allergan on a potential takeout.
Somaiya said a potential sale, in their opinion, is likely dependent on Biogen's... More
Biogen (BIIB) Takeover 'Makes Sense' - Leerink Partners
August 3, 2016 7:38 AM EDTLeerink Partners analyst Geoffrey Porges weighed in on Biogen (NASDAQ: BIIB) amid reports Tuesday that the company is in talks with Merck and Allergan on a potential takeout.
Porges said while they have no information to confirm the suggestions that Merck (MP) and Allergan (OP) are among the potential suitors, it certainly makes sense to us.
"In our recent notes we have suggested... More
Tecfidera IP the Major Risk of Biogen (BIIB) Takeout - Baird
August 3, 2016 7:17 AM EDTBaird analyst Brian Skorney weighed in on Biogen (NASDAQ: BIIB) amid reports Tuesday that the company is in talks with Merck and Allergan on a potential takeout.
Skorney commented, "Though we are not surprised that takeout discussions are taking place, we question the... More
Standpoint Research Downgrades Biogen (BIIB) to Hold
August 2, 2016 3:31 PM EDTStandpoint Research downgraded Biogen (NASDAQ: BIIB) from Buy to Hold.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $301.83 yesterday.
... MoreiShares Nasdaq Biotechnology (IBB) Spikes on Biogen Headlines
August 2, 2016 2:52 PM EDTiShares Nasdaq Biotechnology (NASDAQ: IBB) spikes higher on reports Merck (NYSE: MRK) and Allergan (NYSE: AGN) were looking at Biogen (NASDAQ: BIIB)
... MoreBiogen (BIIB) Peers on Watch Amid M&A Chatter (AMGN) (GILD)
August 2, 2016 2:52 PM EDTBiogen (NASDAQ: BIIB) peers are on watch amid today's M&A chatter. Names include: Celgene (NASDAQ: CELG), Gilead Sciences (NASDAQ: GILD), and Amgen (NASDAQ: AMGN), among others.
... MoreBiogen (BIIB) Shares Active on M&A Chatter
August 2, 2016 2:43 PM EDT(Updated - August 2, 2016 2:46 PM EDT)
Biogen (NASDAQ: BIIB) shares volatile over Merck (NYSE: MRK), Allergan (NYSE: AGN)-related chatter.
UPDATE - Talks were said... More
Biogen (BIIB) Draws Takeover Interest from Allergan (AGN), Merck (MRK) - DJ
August 2, 2016 2:43 PM EDT(Updated - August 2, 2016 2:49 PM EDT)
Biogen (Nasdaq: BIIB) attracted takeover interest from Allergan (NYSE: AGN) and Merck (NYSE: MRK), according to Dow Jones, citing sources. The two companies reportedly... More
Biogen (BIIB) triggers LUDP trading pause
August 2, 2016 2:43 PM EDTBiogen (NASDAQ: BIIB) triggers LUDP trading pause.
... More